Cargando…

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study

MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine intended for the prevention of invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y in individuals aged 6 weeks and above. This Phase II, randomized, open-label, multicenter, exploratory study assessed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirstein, Judith, Pina, Miriam, Pan, Judy, Jordanov, Emilia, Dhingra, Mandeep S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7482642/ https://www.ncbi.nlm.nih.gov/pubmed/32233961 http://dx.doi.org/10.1080/21645515.2020.1733868

Ejemplares similares

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
por: Vesikari, Timo, et al.
Publicado: (2020)

2462. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Individuals 56 Years of Age and Older
por: Jeanfreau, Robert, et al.
Publicado: (2018)

Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study
por: Áñez, Germán, et al.
Publicado: (2020)

2725. Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Adolescents and Adults
por: Hedrick, James, et al.
Publicado: (2019)

2723. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adolescents 10–17 Years of Age
por: Peterson, James, et al.
Publicado: (2019)

2719. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Adults 18–55 Years of Age
por: Peterson, James, et al.
Publicado: (2019)

2724. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Healthy Meningococcal Vaccine-Naïve Children (2–9 Years)
por: Simon, Michael W, et al.
Publicado: (2019)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
por: van der Vliet, D., et al.
Publicado: (2021)

1967. Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) When Co-administered with Other Vaccines in Healthy Adolescents
por: Hedrick, James, et al.
Publicado: (2018)

03. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered as a Booster Dose in Adults and Adolescents Vaccinated Against Meningococcal Disease 3 - 6 Years Earlier
por: Peterson, James, et al.
Publicado: (2021)

04. Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered in Meningococcal Vaccine-Naive Participants Across a Broad Age Range (2-55 Years) in Japan
por: Matsuoka, Osamu, et al.
Publicado: (2021)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
por: Knuf, Markus, et al.
Publicado: (2022)

Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older
por: Neveu, David, et al.
Publicado: (2023)

Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®
por: Kensinger, Richard, et al.
Publicado: (2022)

1243. Semi-Quantitative Benefit-Risk Assessment for a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals 2 Years of Age and Older
por: Neveu, David, et al.
Publicado: (2020)

1139. Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Compared to a Meningococcal Reference Vaccine (MCV4-TT) in Healthy Adolescents
por: Díez-Domingo, Javier, et al.
Publicado: (2023)

Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study
por: Robertson, Corwin A., et al.
Publicado: (2023)

Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study
por: Zambrano, Betzana, et al.
Publicado: (2023)

1157. Immune Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) 5 Years After Primary Vaccination of Adults ≥59 Years of Age
por: Robertson, Corwin A, et al.
Publicado: (2023)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

3. A Review of the Clinical Development of MenACWY-TT, a Quadrivalent Meningococcal Vaccine Conjugated to Tetanus Toxoid, in Adolescents
por: Peyrani, Paula, et al.
Publicado: (2020)

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
por: Marshall, Gary S., et al.
Publicado: (2022)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study
por: Dhingra, M. S., et al.
Publicado: (2021)

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10–25 Years of Age
por: Halperin, Scott A., et al.
Publicado: (2014)

Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2–9 Years of Age: A Phase III, Randomized Study
por: Baccarini, Carmen I., et al.
Publicado: (2020)

Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2016)

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
por: Dbaibo, Ghassan, et al.
Publicado: (2013)

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study
por: Knuf, Markus, et al.
Publicado: (2013)

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2017)

2461. Safety of Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid-Conjugate Vaccine in Adolescents
por: Myers, Tanya, et al.
Publicado: (2018)

A rare case of cellulitis after tetanus toxoid (TT) vaccination
por: AlBassri, Tala K., et al.
Publicado: (2020)

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study
por: Piazza, Franco M., et al.
Publicado: (2021)

1089 Safety and Immunogenicity of DTaP-IPV (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Combined with Inactivated Poliovirus Vaccine) Compared to DAPTACEL(®) (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL(®) (Poliovirus Vaccine Inactivated) as the 5th Dose in Children 4 to 6 Years of Age
por: Smith, Michael, et al.
Publicado: (2014)

The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: A randomized, controlled non-inferiority study
por: Dbaibo, Ghassan, et al.
Publicado: (2012)

The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults
por: Reyes, Mari Rose Aplasca-De Los, et al.
Publicado: (2012)

Comparative Immunogenicity of the Tetanus Toxoid and Recombinant Tetanus Vaccines in Mice, Rats, and Cynomolgus Monkeys
por: Yu, Rui, et al.
Publicado: (2016)

Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali
por: Basta, Nicole E., et al.
Publicado: (2015)

Comparison of Immune Responses to Two Quadrivalent Meningococcal Conjugate Vaccines (CRM197 and Diphtheria Toxoid) in Healthy Adults
por: Kim, Han Wool, et al.
Publicado: (2019)

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
por: Knuf, Markus, et al.
Publicado: (2012)

Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial
por: Borja-Tabora, Charissa Fay Corazon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p8k31uq730be1ee5ep0d6euajk